Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena

Conclusion A significant number of patients who meet currently approved indications for anti-IL5 mAbs show suboptimal response to them in real-life clinical practice, particularly if they are on high doses of prednisone. Monitoring blood eosinophil count is not helpful to identify these patients. The concern of worsening of symptoms associated with immune-complex mediated complement activation in a small proportion of these patients highlights the relevance of recognising airway autoimmune phenomena and this requires further evaluation.

http://erj.ersjournals.com/cgi/content/short/56/4/2000117?rss=1

Source: European Respiratory Journal - October 8, 2020 Category: Respiratory Medicine Authors: Mukherjee, M., Forero, D. F., Tran, S., Boulay, M.-E., Bertrand, M., Bhalla, A., Cherukat, J., Al-Hayyan, H., Ayoub, A., Revill, S. D., Javkar, T., Radford, K., Kjarsgaard, M., Huang, C., Dvorkin-Gheva, A., Ask, K., Olivenstein, R., Dendukuri, N., Lemiere Tags: Asthma and allergy Original Articles: Asthma Source Type: research